Article Text

Download PDFPDF
Randomised controlled trial
Ramipril improves walking times and quality of life in patients with stable intermittent claudication
  1. Julie Brittenden
  1. Division of Applied Medicine, University of Aberdeen, Aberdeen, UK
  1. Correspondence to: Professor Julie Brittenden, Division of Applied Medicine, University of Aberdeen, Polwarth Building, Room 4016, Foresterhill, Aberdeen AB12 2ZN, UK; j.brittenden{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Intermittent claudication (IC) is a common condition that may be associated with significant disability and reduction in quality of life. Pharmacological options for the treatment of the symptoms of this condition are very limited. Naftidrofuryl oxalate is recommended in the National Institute for Health and Care Excellence (NICE) guidelines,1 and while this has been shown to improve pain-free and maximal walking distances, its effect, if any, on quality of life is unknown. ACE inhibitors (ACEI) are believed to have the potential to improve blood flow, endothelial function, and alter muscle metabolism and structure. Previous small studies involving ACEI have shown …

View Full Text


  • Competing interests None.